BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

834 related articles for article (PubMed ID: 10730528)

  • 1. The efficacy of intravenous pulse cyclophosphamide in the treatment of severe lupus nephritis in children.
    Tangnararatchakit K; Tapaneya-Olarn C; Tapaneya-Olarn W
    J Med Assoc Thai; 1999 Nov; 82 Suppl 1():S104-10. PubMed ID: 10730528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparison of various cyclophosphamide treatment regimens on the course and outcome of lupus nephritis ].
    Petrović R; Stojanović R; Novicić-Sasić D; Dimitrijević J; Pavlović S; Stojković D; Palić-Obradović D; Stevanović G; Prodanović S
    Srp Arh Celok Lek; 2002 Aug; 130 Suppl 3():19-25. PubMed ID: 12583309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial.
    Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; de Ramon Garrido E; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
    Arthritis Rheum; 2004 Dec; 50(12):3934-40. PubMed ID: 15593207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: a prospective five-year study.
    Valeri A; Radhakrishnan J; Estes D; D'Agati V; Kopelman R; Pernis A; Flis R; Pirani C; Appel GB
    Clin Nephrol; 1994 Aug; 42(2):71-8. PubMed ID: 7955581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.
    Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; Garrido Ed Ede R; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
    Arthritis Rheum; 2002 Aug; 46(8):2121-31. PubMed ID: 12209517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous cyclophosphamide for lupus nephritis in Thai children.
    Vachvanichsanong P; Dissaneewate P; Winn T
    Scand J Rheumatol; 2004; 33(5):339-42. PubMed ID: 15513684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulse cyclophospamide in severe lupus nephritis: Southern Indian experience.
    Das U; Dakshina Murty KV; Prasad N; Prayag A
    Saudi J Kidney Dis Transpl; 2010 Mar; 21(2):372-8. PubMed ID: 20228536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide.
    Mok CC; Ying KY; Ng WL; Lee KW; To CH; Lau CS; Wong RW; Au TC
    Am J Med; 2006 Apr; 119(4):355.e25-33. PubMed ID: 16564783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effects of combination treatment with fludarabine and low-dose pulse cyclophosphamide in patients with lupus nephritis.
    Illei GG; Yarboro CH; Kuroiwa T; Schlimgen R; Austin HA; Tisdale JF; Chitkara P; Fleisher T; Klippel JH; Balow JE; Boumpas DT
    Rheumatology (Oxford); 2007 Jun; 46(6):952-6. PubMed ID: 17317716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of diffuse proliferative lupus nephritis: an Indian experience.
    Abraham MA; Korula A; Arun KN; Jayakrishnan K; John GT; Thomas PP; Jacob CK
    Natl Med J India; 1997; 10(6):273-5. PubMed ID: 9481097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunosuppressive treatment of the glomerulonephritis of systemic lupus.
    Faedda R; Palomba D; Satta A; Pirisi M; Tanda F; Bartoli E
    Clin Nephrol; 1995 Dec; 44(6):367-75. PubMed ID: 8719548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis.
    Grootscholten C; Bajema IM; Florquin S; Steenbergen EJ; Peutz-Kootstra CJ; Goldschmeding R; Bijl M; Hagen EC; Van Houwelingen HC; Derksen RH; Berden JH;
    Arthritis Rheum; 2007 Mar; 56(3):924-37. PubMed ID: 17328070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous pulse cyclophosphamide in the treatment of type IV lupus nephritis.
    Eiser AR; Grishman E; Dreznin S
    Clin Nephrol; 1993 Sep; 40(3):155-9. PubMed ID: 8403570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Intravenous cyclophosphamide in lupus nephritis: twenty years reducing dose].
    Frutos MA; Martín Gómez A; de Ramón E; Camps MT; Valera A; García I; Fernández Nebro A
    Nefrologia; 2007; 27(1):12-22. PubMed ID: 17402875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors of diffuse proliferative lupus nephritis.
    Lim CS; Chin HJ; Jung YC; Kim YS; Ahn C; Han JS; Kim S; Lee JS
    Clin Nephrol; 1999 Sep; 52(3):139-47. PubMed ID: 10499308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognosis of biopsy-proven lupus nephritis in chinese patients: long term follow-up of 86 cases.
    Shen K; Yu Y; Tang Z; Liu Z; Li L
    Chin Med J (Engl); 1997 Jul; 110(7):502-7. PubMed ID: 9594205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis.
    Mok CC; Ying KY; Tang S; Leung CY; Lee KW; Ng WL; Wong RW; Lau CS
    Arthritis Rheum; 2004 Aug; 50(8):2559-68. PubMed ID: 15334470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis.
    Yee CS; Gordon C; Dostal C; Petera P; Dadoniene J; Griffiths B; Rozman B; Isenberg DA; Sturfelt G; Nived O; Turney JH; Venalis A; Adu D; Smolen JS; Emery P
    Ann Rheum Dis; 2004 May; 63(5):525-9. PubMed ID: 15082482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical, biochemical and pathological predictors of poor response to intravenous cyclophosphamide in patients with proliferative lupus nephritis.
    Conlon PJ; Fischer CA; Levesque MC; Smith SR; St Clair EW; Allen NB; Fleming JA; Howell DN
    Clin Nephrol; 1996 Sep; 46(3):170-5. PubMed ID: 8879851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy and safety of quadruple therapy in childhood diffuse proliferative lupus nephritis.
    Demircin G; Oner A; Erdoğan O; Delibaş A; Baysun S; Bülbül M; Bek K; Oksal A
    Ren Fail; 2008; 30(6):603-9. PubMed ID: 18661410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.